Glenmark Pharmaceuticals Limited (GLENMARK.NS) NSE
Currency In INR
- General
- Statistics
- Historical Data
- Profile
- Financials
Glenmark Pharmaceuticals Limited
Address
Glenmark House
Mumbai, MA 400099
India
Phone
91 22 4018 9999
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Employees
16946
First IPO Date
July 01, 2002
Key Executives
| Name | Title | Pay | Year Born |
| Glenn Mario Saldanha | Chairman, MD & Chief Executive Officer | 192.2M | 1970 |
| Cherylann Maria Pinto | Executive Director of Corporate Services & Executive Director | 65.4M | 1967 |
| Anurag Mantri | Global CFO & Executive Director | 97.21M | 1971 |
| Alind Sharma | President and Chief Human Resources Officer | 0 | 1971 |
| Alok Malik | President & Business Head of India Formulations | 0 | N/A |
| Brijlal Motwani | President & Chief Quality Officer | 0 | N/A |
| Christoph Stoller | President and Business Head of Europe & Emerging Markets | 0 | N/A |
| Marc T. Kikuchi | President and Business Head of North America | 0 | 1970 |
| Samir Salauddin Kazi | Executive VP & Head of Legal, Compliance & Intellectual Property | 0 | 1975 |
| Ulhas R. Dhuppad | President & Head of Global Pharmaceutical Development | 0 | 1967 |
| Utkarsh Gandhi | Senior General Manager of Investor Relations | 0 | N/A |
| Rashmi Khandelwal | Company Secretary & Compliance Officer | 0 | N/A |
| Shweta Munjal | Chief Communications & CSR Officer | 0 | N/A |
| Indrajit Bose | President & Chief Quality Officer | 0 | N/A |
Description
Glenmark Pharmaceuticals Limited, including its associated entities, is a global pharmaceutical company specializing in the research, development, production, and marketing of medicinal products. Its operational reach spans India, North America, Latin America, Europe, and other international regions. The company's diverse offerings comprise both branded and generic drug formulations, with a strategic emphasis on therapeutic areas such as dermatology, respiratory conditions, and oncology. Additionally, Glenmark manufactures and supplies a variety of active pharmaceutical ingredients. The company's robust product pipeline includes several investigational therapies. Among its clinical-stage assets are ISB 830 (telazorlimab), an OX40 antagonist monoclonal antibody currently in Phase 2b trials for atopic dermatitis; ISB 1302, a HER2 x CD3 bispecific antibody undergoing Phase 1/2 studies for metastatic HER2-positive breast cancer; and ISB 1342, a CD38 x CD3 bispecific antibody in Phase 1 development for relapsed/refractory multiple myeloma. In its preclinical pipeline, Glenmark is advancing ISB 880 for anti-inflammatory applications; the T-cell engagers ISB 1908 and ISB 1909 for oncology indications; ISB 1442, an innate immune engager also targeting oncology; and GRC 39815, a retinoid-related orphan receptor gamma inhibitor aimed at treating chronic obstructive pulmonary disorder (COPD). Among its commercially available products is Ryaltris nasal spray, prescribed for allergic rhinitis. Founded in 1977, Glenmark Pharmaceuticals Limited is headquartered in Mumbai, India.
